Non-cancer therapeutic antibodies

Since the first transfer of immunity similar to 100 years ago, passive antibody therapy has been at the centre of the treatment of infectious diseases. The realisation that antibodies formed a backbone on which ancillary molecules could be carried was not long to follow. Since then, mAbs, in their pure form, have formed the basis of various immunotherapeutic approaches applied to a broad spectrum of indications. The antibody field is of recent developing a strong a rich foundation with new strategies and novel targets opening the way for application in numerous clinical settings, both in adjuvant setting and as gold standard. The scope of this review is to assess the current state of non-cancer antibody approaches in current clinical practice with respect to clinical indication, discussing new developments in their clinical application.